Research by UTMB’s Jacques Baillargeon finds that exposure to testosterone therapy over a five-year period does not increase the risk of aggressive prostate cancer. Baillargeon’s research also found the risk of high-grade prostate cancer does not increase according to the total number of testosterone injections.